Physician profile
Sameh Refat Gaballa
NPI 1659534238
$214,435.71
in general payments reported to CMS, 2019-2025
26 companies · $36K in 2025
The $36K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $4,900 · 2021: $23K · 2022: $30K · 2023: $31K · 2024: $49K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $32K · Travel and Lodging: $14K · Honoraria: $5,840 · Food and Beverage: $3,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,241.25 |
| Consulting Fee | $32,294.50 |
| Travel and Lodging | $13,641.85 |
| Honoraria | $5,840.00 |
| Food and Beverage | $3,383.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $60,432.59 | 2021-2025 | |
| Lilly USA, LLC | $49,472.47 | 2022-2025 | Jaypirca |
| Janssen Biotech, INC. | $25,040.00 | 2019 | |
| Epizyme, INC. | $11,715.05 | 2020-2025 | Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $10,660.81 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $9,560.10 | 2023-2024 | |
| Abbvie INC. | $7,283.62 | 2021-2025 | |
| Incyte Corporation | $7,206.86 | 2025 | Monjuvi |
| Adaptive Biotechnologies Corporation | $5,674.86 | 2025 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $4,979.32 | 2023-2024 | Tazverik |
| Astrazeneca Pharmaceuticals LP | $4,948.97 | 2019-2025 | Calquence |
| Janssen Scientific Affairs, LLC | $4,606.10 | 2019 | |
| Gilead Sciences, INC. | $2,700.00 | 2023 | Tecartus |
| Beigene USA, INC. | $2,571.13 | 2020-2023 | Brukinsa |
| Genentech USA, INC. | $2,303.43 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $2,108.55 | 2023-2024 | Epkinly |
| Tg Therapeutics, INC. | $1,800.00 | 2021-2022 | |
| Beigene, LTD. | $812.50 | 2021 | |
| Celgene Corporation | $303.22 | 2019-2025 | |
| Kite Pharma, INC. | $125.00 | 2024 | |
| Sobi, INC | $63.62 | 2025 | |
| Rigel Pharmaceuticals, INC. | $39.34 | 2023 | Tavalisse, Rezlidhia |
| Morphosys, US INC. | $14.88 | 2023 | Monjuvi |
| Seagen INC. | $13.29 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Gaballa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.